The 503A Bulks List is one of the most consequential — and least understood — regulatory mechanisms in the research peptide space. It determines which substances licensed compounding pharmacies can legally prepare for individual patients under a physician's prescription, without those substances having received full FDA approval as finished drug products.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies may prepare customized medications for individual patients. However, they may only use bulk drug substances that appear on a specific FDA-maintained list, or that have been nominated for inclusion and are pending review. The 503A Bulks List is that list — and getting a peptide onto it is the regulatory pathway that would transform these compounds from grey-market research chemicals into regulated pharmaceutical ingredients.

The nomination process begins when any interested party — a patient, physician, pharmacy, or advocacy organization — submits a formal nomination to the FDA requesting that a substance be considered for the 503A Bulks List. The FDA then evaluates the nomination against a set of criteria that includes: whether there is a clinical need for the compounded preparation, whether the substance has been studied sufficiently to assess its safety profile, and whether the substance is a copy of a commercially available FDA-approved product (which would generally disqualify it).

After internal review, the FDA refers nominated substances to its Pharmacy Compounding Advisory Committee (PCAC), an independent panel of experts that includes physicians, pharmacists, patient advocates, and scientists. The PCAC reviews the available evidence and votes on whether the substance should be added to the list. The committee’s vote is advisory; the FDA makes the final decision.

The July 23–24, 2026 PCAC meeting reviewed seven peptides, including BPC-157, KPV, and TB-500. The panel’s votes in favor of six of the seven peptides, including 8–6 votes for BPC-157, KPV and TB-500, represent a meaningful step forward, but it is not the final step. Following a favorable PCAC vote, the FDA must publish a proposed rule in the Federal Register, accept public comments, and issue a final rule before the substance is formally added to the 503A Bulks List. This process usually takes many months.

For the research community, the 503A pathway matters even before a substance is formally listed. The nomination and review process generates a substantial body of public scientific documentation — including the FDA's own safety analyses and the PCAC's deliberations — that enriches the research literature and provides a more rigorous evidentiary foundation for in vitro studies.

All compounds discussed are for laboratory research use only and are not intended for human or animal consumption.